Recap: United Therapeutics Q1 Earnings

United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 3, 2023 at 06:00 AM. Here’s what…

byBenzinga Insights

May 3, 2023

1 minute read

United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 3, 2023 at 06:00 AM.

Here’s what investors need to know about the announcement.

Earnings

United Therapeutics beat estimated earnings by 7.52%, reporting an EPS of $4.86 versus an estimate of $4.52.

Revenue was up $45.00 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $1.84 which was followed by a 1.89% increase in the share price the next day.

Here’s a look at United Therapeutics’s past performance:

Quarter	Q4 2022	Q3 2022	Q2 2022	Q1 2022
EPS Estimate	4.51	3.89	4.12	3.34
EPS Actual	2.67	4.91	2.41	5.03
Revenue Estimate	519.21M	493.20M	461.06M	420.02M
Revenue Actual	491.50M	516.00M	466.90M	461.90M

To track all earnings releases for United Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Why Investors Are Dumping CEVA Shares Today

By Nabaparna Bhattacharya

August 9, 11:22 AM

CEVA, Inc. (NASDAQ: CEVA) reported a second-quarter FY23 revenue decline of 21% year-on-year to $26.17 million,

CEVA

Earnings

Transphorm: Q4 Earnings Insights

By Benzinga Insights

June 27, 4:40 PM

Transphorm (NASDAQ:TGAN) reported its Q4 earnings results on Tuesday, June 27, 2023 at 04:30 PM. Here’s what investors…

TGAN

Israeli ‘Cannabis Sticks’ Maker Reports Financial Results For 2023 Following Reverse Takeover

By Jelena Martinovic

April 8, 12:29 PM

Israeli technology and cannabinoid company StickIt Technologies announced on Monday its financial results for the year ended Dec. 31, 2023. Revenue for the fiscal 2023 amounted to CA$203 000 ($149,300), compared to CA$564 000, in the prior year. The company called 2023 a "notable year" following the "completion of a reverse takeover on Oct. 23, 2023, positioning StickIt for accelerated growth and market expansion." Simultaneously the company completed a financing of CA$441,000, consisting of 1,024,628 subscription receipts for CA$0.4304 each, which were converted on a 1:1 basis into the company's common shares.StickIt, the developer exclusivity and patent protected of "Cannabis Sticks," debuted on the Canadian Securities Exchange (CSE), in the same month.

CSE:STKT